Cagrilintide cagrilintide PHASE3
Drug Profile
ModalityPeptide
RouteSC
Therapy AreaCVRM
Peak Sales Est$5000M
Formulations[]
Companies
NVO (ORIGINATOR)100%
Mechanism: GLP-1/Amylin dual agonist
Expert: Dual agonist targeting both GLP-1 and amylin receptors, providing synergistic effects on satiety, gastric emptying, and glucose homeostasis through complementary central and peripheral mechanisms.
Everyday: Combines two hormones that work together to reduce appetite and blood sugar more effectively than either alone.
Targets: ["GLP-1","AMYLIN"]
Programs (1)
IndicationStageKey StudyRegional Status
ObesityPHASE3RENEW[]
Upcoming Catalysts (1)
Cagrilintide - Obesity - Ph3 - Start (RENEW) 2026
Notes
Long-acting amylin analog. RENEW Phase 3 program planned. Standalone development separate from CagriSema combination.
Data from Supabase · Updated 2026-03-24